Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02286687 · ClinicalTrials.gov registry record · Phase 2
Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes
A Phase 2 study of Advanced Malignant Neoplasm and Metastatic Malignant Neoplasm, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
- 1
- Study location
NCT02286687: Active Phase 2 study of Advanced Malignant Neoplasm and Metastatic Malignant Neoplasm, sponsored by M.D. Anderson Cancer Center.
NCT02286687 is a Phase 2 study of Advanced Malignant Neoplasm and Metastatic Malignant Neoplasm that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 150 participants, below the 167-participant average among 16 other Advanced Malignant Neoplasm trials with a reported enrollment target (10% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02286687, a Phase 2 study of Advanced Malignant Neoplasm and Metastatic Malignant Neoplasm, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial studies how well talazoparib works in treating patients with cancers that have returned after a period of improvement, do not respond to treatment, or have spread to other parts of the body, and have alterations in the breast cancer, early onset (BRCA) genes. Talazoparib may cause tumor cells to die by blocking an enzyme that protects the tumor cells from damage.
Primary Outcome
Evaluated separately in each cohort. Calculated using posterior probabilities along with corresponding credible intervals.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Talazoparib
- OTHER Pharmacological Study
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2014-12-22 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 2 |
What the registry record for NCT02286687 still lists
NCT02286687 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 167-participant average among 16 other Advanced Malignant Neoplasm trials with a reported enrollment target (10% lower).
The record links to 8 conditions, with Advanced Malignant Neoplasm appearing as the primary indexed condition, and to 3 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02286687 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT02286687 about?
NCT02286687 is a clinical study titled "Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes". This phase II trial studies how well talazoparib works in treating patients with cancers that have returned after a period of improvement, do not respond to treatment, or have spread to other parts of the body, and have alterations in the breast cancer, early onset (BRCA) genes. Talazoparib may caus...
What is the current status of trial NCT02286687?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2014-12-22. Estimated completion is 2026-12-31.
What conditions does trial NCT02286687 study?
This clinical trial studies the following conditions: Advanced Malignant Neoplasm, Metastatic Malignant Neoplasm, Recurrent Malignant Neoplasm, BRCA1 Gene Mutation, BRCA2 Gene Mutation.
What interventions are being tested in trial NCT02286687?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Talazoparib (DRUG), Pharmacological Study (OTHER).
Who is sponsoring clinical trial NCT02286687?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02286687 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Malignant Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02286687's enrollment target sits among peer trials
150 8th of 16 higher than 9 of 16 other Advanced Malignant Neoplasm trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Malignant Neoplasm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Physical Activity and Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Advanced Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Haloperidol With or Without Chlorpromazine in Treating Delirium in Patients With Advanced, Metastatic, or Recurrent Cancer
ACTIVE NOT RECRUITING · Phase 2
-
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RECRUITING · Phase 1
-
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
RECRUITING · Phase 1
-
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
RECRUITING · Phase 1
-
Preference of Room Setting and Waiting Time in Patients With Advanced, Locally Advanced, or Metastatic Cancer and Their Caregivers Who Are Seen in the Outpatient Supportive/Palliative Care Center
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI